What ENEA Tech e Biomedical does

Fondazione ENEA Tech e Biomedical is an Italian private foundation supervised by the Ministry of Enterprises and Made in Italy (MIMIT) and the Ministry of Health, headquartered in Rome. It operates as a state-backed technology transfer and biomedical investment vehicle, deploying capital through two principal programs: the Technology Transfer Fund (covering green/circular economy, IT, agri-tech, and deep tech) and the Biomedical Industrial Research and Development Fund (covering drugs, vaccines, diagnostics, and medical devices). Its functional role is to bridge Italian academic and clinical biomedical research with industrial commercialization, funding startups, spin-offs, and SMEs through equity investments, co-investments (notably with CDP Venture Capital), and non-repayable grants up to €20 million per project.

The foundation's portfolio reflects a deliberate diversification across high-value biomedical subsectors. It wholly owns Holostem Terapie Avanzate (cell and gene therapy for rare diseases), led a €7.15 million round into Cellply (automated QC for advanced therapy medicinal products), participated in WISE S.p.A.'s €30 million Series D (implantable neural electrodes and brain-computer interfaces) and BionIT Labs' €5.5 million round (bionic prosthetics), and co-acquired a stake in Oversonic Robotics alongside STMicroelectronics (cognitive humanoid robotics). Geographic activity is anchored in Italy with explicit transatlantic outreach toward the US and Latin America.

The foundation does not sell products or services; its revenue model is the deployment of state-allocated and partner capital into portfolio companies. Governance is exercised through a board including figures such as Giovanni Tria, Sergio Abrignani, and Paolo Bonaretti, with compliance functions (RPCT, RASA) formalized. Its strategic posture combines financial returns with national-policy objectives around Italy's life sciences sovereignty, biotech industrial development, and attraction of foreign biomedical investment.

Name

ENEA Tech e Biomedical

Legal name

Fondazione ENEA Tech e Biomedical

Website

https://eneatechbiomedical.it

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

ENEA Tech e Biomedical is an Italian government-supervised private foundation that invests in technology transfer and biomedical R&D, deploying grants and equity into Italian startups, spin-offs, and SMEs across cell and gene therapy, medical devices, neuromodulation, and deep tech.

Ownership category

akta.pro rank

Product category

Biomedical Research Investment

NAICS

Health and Welfare Funds (52512), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Investment Advice (6282), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

akta.pro secondary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

• Biomedical research funding
• Technology transfer investment
• Life sciences venture capital
• Biomedical innovation grants
• Industrial R&D funding

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Technology Transfer Investments: The foundation supports investments in technology transfer, biomedical research, and industrial development through participation in startups, spin-offs, and SMEs with high growth potential. It operates through the Technology Transfer Fund and the Biomedical Industrial Development Fund.

Marketing channels4 records

Core offering

Fondazione ENEA Tech e Biomedical is an Italian private foundation that operates investment funds (the Technology Transfer Fund and the Biomedical Industrial Research and Development Fund) to support startups, spin-offs, and SMEs in the biomedical sector. It provides equity investments, co-investments, and non-repayable contributions for industrial research and experimental development projects in pharmaceuticals, medical devices, diagnostics, cell and gene therapy, and regenerative medicine, while also publishing public calls for proposals offering contributions up to EUR 20 million per project.

Product overview

ENEA Tech e Biomedical is a private Italian foundation supervised by the Ministry of Enterprises and Made in Italy and Ministry of Health. It is not a product company but rather an investment and funding vehicle focused on technology transfer, biomedical research, and industrial development in Italy. The foundation supports startups, spin-offs, and SMEs operating in green and circular economy, Information Technology, agri-tech, and deep tech sectors through its Technology Transfer Fund, as well as industrial projects for drugs, vaccines, diagnostic products, and medical devices through its Biomedical Fund. The foundation also publishes public calls for proposals offering non-repayable contributions (up to €20 million per project with a minimum project value of €20 million) for industrial research and experimental development projects in the biomedical sector, drawing from a €40 million Biomedical Fund. ENEA Tech e Biomedical does not develop or sell its own commercial products or software platforms.

Differentiator

Problem solved

Functional benefit

Products and services

• Technology Transfer Fund (Fondo Trasferimento Tecnologico)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered strategic and governance.

• CellSeed Inc.strategicStrategic or Co-development PartnerCellSeed Inc. is identified as a key company actively involved alongside Foundation ENEA Tech Biomedical in developing and commercializing advanced regenerative medicine technologies in the cell sheet-based gene therapy market in Europe.
• Ministry of Enterprises and Made in ItalygovernanceOthersThe foundation is supervised by Italy's Ministry of Enterprises and Made in Italy (MIMIT) and Ministry of Health, which provide institutional oversight and strategic direction for the foundation's investment activities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Panakès Partners: Italian/European life sciences venture capital firm investing in early-stage medical devices, diagnostics, and therapeutics. Closely comparable in its focus on biomedical startups across Italy and Europe with a similar check size and stage.
• CDP Venture Capital: Italian state-backed venture capital arm of Cassa Depositi e Prestiti. Directly co-invests with ENEA Tech in biomedical rounds (Cellply, BionIT Labs), operates comparable Italian-focused technology transfer funds, and shares the same national mandate to industrialize Italian R&D.
• BioGeneration Ventures: European venture capital firm dedicated to early-stage life sciences, including therapeutics, medtech, and diagnostics. Comparable as a specialist biomedical investor in the same deal universe as ENEA Tech's portfolio.
• Invitalia: Italian national agency for enterprise and investment promotion, operating venture and growth capital vehicles for Italian SMEs and startups. Comparable as a state-backed deployer of patient capital into Italian innovation, with overlapping industrial policy objectives.
• Eureka! Venture SGR: Italian early-stage technology VC investing in deep tech and life sciences. Co-invested with ENEA Tech in WISE's Series D and pursues a similar thesis around technology transfer from Italian research institutions to commercial ventures.
• Indaco Ventures SGR: Italian venture capital manager with a deep tech and life sciences focus. Co-invested alongside ENEA Tech in WISE's €30M Series D and operates a comparable Italian early-stage investment thesis, making it a direct co-investor peer.

Broad incumbents

• EIC Fund (European Innovation Council): EU-level investment vehicle backing breakthrough and deep tech innovation, with a large life sciences allocation. Overlaps with ENEA Tech's portfolio in early-stage biomedical and deep tech, though at EU rather than Italian national level.
• European Investment Fund (EIF): Pan-European fund-of-funds manager with significant life sciences and impact mandates. Operates at greater scale and broader mandate, but overlaps as a public-sector investor in European biomedical innovation.

Others

• Human Technopole: Italian life sciences research foundation funded by the government, with which ENEA Tech has co-organized events. Adjacent as a publicly funded life sciences institution rather than a direct investment competitor.

Emerging players

• Italian Angels for Growth (IAG): Largest Italian business angel network investing in innovative Italian startups, including in life sciences. Adjacent early-stage capital provider that often co-invests with institutional funds in the same deals.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@FondazioneENEATecheBiomedical
• LinkedInlinkedin.com/company/enea-tech-e-biomedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments16 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENEA Tech e Biomedical